[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112014030039A2 - heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos - Google Patents

heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos

Info

Publication number
BR112014030039A2
BR112014030039A2 BR112014030039A BR112014030039A BR112014030039A2 BR 112014030039 A2 BR112014030039 A2 BR 112014030039A2 BR 112014030039 A BR112014030039 A BR 112014030039A BR 112014030039 A BR112014030039 A BR 112014030039A BR 112014030039 A2 BR112014030039 A2 BR 112014030039A2
Authority
BR
Brazil
Prior art keywords
cell responses
bicyclic heterocycles
methods
modulating
disorders
Prior art date
Application number
BR112014030039A
Other languages
English (en)
Inventor
Verhaar Auke
Hommes Daan
Viti Francesca
Van Den Brink Gijs
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of BR112014030039A2 publication Critical patent/BR112014030039A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos” a presente divulgação é dirigida, em parte, a heterociclos bicíclicos, tais co-mo um composto representado pela fórmula i, ia, ib, ii ou iia divulgada neste relató-rio, e a seu uso no tratamento de transtornos médicos, tais como transtornos infla-matórios imunes, tais como doença de crohn, colite ulcerativa, transtornos reumáti-cos, psoríase e alergias. os compostos são considerados para modular respostas de células t.
BR112014030039A 2012-06-01 2013-05-31 heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos BR112014030039A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654398P 2012-06-01 2012-06-01
PCT/EP2013/061328 WO2013178815A1 (en) 2012-06-01 2013-05-31 Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same

Publications (1)

Publication Number Publication Date
BR112014030039A2 true BR112014030039A2 (pt) 2017-06-27

Family

ID=48538005

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030039A BR112014030039A2 (pt) 2012-06-01 2013-05-31 heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos

Country Status (11)

Country Link
US (2) US20150126553A1 (pt)
EP (1) EP2861563B1 (pt)
JP (1) JP2015521195A (pt)
KR (1) KR20150016377A (pt)
CN (1) CN104619687A (pt)
AU (1) AU2013269550A1 (pt)
BR (1) BR112014030039A2 (pt)
CA (1) CA2874919A1 (pt)
IN (1) IN2014DN10214A (pt)
MX (1) MX2014014657A (pt)
WO (1) WO2013178815A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EA020198B1 (ru) 2009-02-16 2014-09-30 Джулиани Интернэшнл Лимитед N-ацетил-(r)-(-)-3-(4-аминофенил)-2-метоксипропионовая кислота, содержащая ее фармацевтическая композиция, способ лечения
CN116602950A (zh) 2012-02-09 2023-08-18 诺格拉制药有限公司 治疗纤维化的方法
IN2014DN08157A (pt) 2012-04-18 2015-05-01 Nogra Pharma Ltd
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
JP7346439B2 (ja) * 2018-03-27 2023-09-19 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｏｘ２ｒ化合物
US11905232B2 (en) 2019-02-08 2024-02-20 Nogra Pharma Limited Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069385A1 (ru) * 1982-05-07 1990-11-15 Научно-исследовательский институт фармакологии АМН СССР Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет
US7868028B2 (en) * 2002-06-17 2011-01-11 Fred Drasner Guanidine compounds as anesthetics and for treatment of nervous system disorders
EP1861377B1 (en) * 2005-03-15 2010-12-29 Pfizer, Inc. Benzimidazolone derivatives as cb2 receptor ligands
CA2619365A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
JP2009523816A (ja) * 2006-01-19 2009-06-25 アボット・ラボラトリーズ ２−イミノ−ベンズイミダゾール類
WO2008036244A1 (en) * 2006-09-18 2008-03-27 The Burham Institute For Medical Research Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands
PT2262778T (pt) * 2008-03-07 2019-11-19 Acraf Derivados de 1-benzil-3-hidroximetilindazolo e utilização dos mesmos no tratamento de doenças baseadas na expressão de mcp-1, cxcr1 e p40
AU2009221063B2 (en) * 2008-03-07 2013-03-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1

Also Published As

Publication number Publication date
US20170183313A1 (en) 2017-06-29
IN2014DN10214A (pt) 2015-08-07
EP2861563A1 (en) 2015-04-22
WO2013178815A1 (en) 2013-12-05
EP2861563B1 (en) 2017-07-12
CN104619687A (zh) 2015-05-13
JP2015521195A (ja) 2015-07-27
MX2014014657A (es) 2015-08-10
US20150126553A1 (en) 2015-05-07
CA2874919A1 (en) 2013-12-05
KR20150016377A (ko) 2015-02-11
AU2013269550A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
BR112014030039A2 (pt) heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos
BR112014030050A2 (pt) heterociclos capazes de modular as respostas das células t, e métodos de utilizar os mesmos
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
BR112015023760A2 (pt) compostos e composições terapêuticas
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
EA201590999A1 (ru) Пирролобензодиазепины и их конъюгаты
EA201590881A1 (ru) Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2
BR112015019276A2 (pt) compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
EA201201648A1 (ru) Стимуляторы sgc
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MY165584A (en) Ampk-activating heterocyclic compounds and methods for using the same
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
BR112015002706A8 (pt) Niclosamida e seus derivados para uso no tratamento de tumores sólidos
NZ629914A (en) New derivatives of 5-aminolevulinic acid and their use as photosensitizing agents
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
GT201700220A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112016016130A2 (pt) Compostos e métodos
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
EA201300997A1 (ru) ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.